Facebook Twitter Newsletter Linkedin RSS

Portail de la presse

Inpharmatica announces appointment of John Lisle as Chief Executive Officer

Press and analyst contact:
Andrew Lloyd & Associates
Andrew Lloyd / Guillaume Zeller
Tel: +33  1 56 54 07 00
Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser. / Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser.

Inpharmatica    John Lisle, Chief Executive Officer
 Tel: +44 (0)20 7074 4600

Inpharmatica announces appointment of John Lisle as Chief Executive Officer

London, UK, 19 January 2005 - Inpharmatica, the selective drug discovery company, today announces the appointment of John Lisle as Chief Executive Officer.

John has over 15 years' experience in the pharmaceuticals and life sciences industry.  Most recently he was Chief Executive Officer of Profile Therapeutics plc and previously held a variety of commercial roles at GlaxoSmithKline and Astra Zeneca.

Following John's appointment, Malcolm Weir, Inpharmatica's current Chief Executive will remain on the Board as Chief Scientific Officer leading Inpharmatica's research and drug discovery activities.
Commenting on the appointment, Edwin Moses, Chairman, said:
"John's extensive commercial and corporate experience within the life sciences arena will be a valuable asset to us as Inpharmatica enters a new and exciting stage of its development. I welcome him to the Board."

Inpharmatica : (www.inpharmatica.com)
Founded in 1998, Inpharmatica Ltd is a selective drug discovery company using predictive technologies to improve speed and productivity.  Focusing on highly druggable targets, its unique proprietary platform, PharmaCarta(TM), is an integrated suite of informatics-based technologies fully capable of rapid gene to candidate operations.  Inpharmatica's lead discovery programme is focused on generating pre-clinical candidates against 16 novel nuclear receptors - proteins widely considered to be both druggable and of high therapeutic interest.  Other significant programmes include novel secreted proteins/antibody targets, ion channels, P450 enzymes, metalloproteinases and progestin receptors.

The Company employs approximately 100 professionals at its UK locations in London and Cambridge, with business development headed in North America.  Inpharmatica has raised some GBP 48m from leading venture capitalists and has sales/collaboration partnerships with Serono, Pfizer, GSK, Aventis, P&G, Daiichi, Riken, Taisho, Chugai, MDL, Ionix, CellZome and Galapagos.
--
Stéphanie CHANE CHICK TE

ANDREW LLOYD & ASSOCIATES
http://www.ala.com

55 rue Boissonade
75014 PARIS
FRANCE

Tel  : +33-1 56 54 07 00
Fax : +33-1 56 54 07 01

Brighton Business Centre
95 Ditchling Road
Brighton BN 1 4ST
ENGLAND

Tel:  +44-1273 675100
Fax: +44-1273 675400

email : Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser.

INTERNATIONAL TECHNOLOGY MARKETS            STRATEGY & COMMUNICATIONS